Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
2 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
4 Alcoholism 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
5 Alzheimer disease 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
6 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
7 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
8 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
9 Apelin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
10 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
11 Apoptosis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
12 Autophagy - animal 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
13 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
14 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
15 B cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
16 Bladder cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
17 Breast cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
18 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
19 cAMP signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
20 Cellular senescence 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
21 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
22 Central carbon metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
23 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
24 cGMP-PKG signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
25 Chemical carcinogenesis - reactive oxygen species 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
26 Chemical carcinogenesis - receptor activation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
27 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
28 Chemokine signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
29 Choline metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
30 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
31 Cholinergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
32 Chronic myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
33 Colorectal cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
34 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
35 Cushing syndrome 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
36 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
37 EGFR tyrosine kinase inhibitor resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
38 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
39 Endocrine resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
40 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
41 Endometrial cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
42 ErbB signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
43 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
44 Estrogen signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
45 Fc epsilon RI signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
46 Fc gamma R-mediated phagocytosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
47 Focal adhesion 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
48 FoxO signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
49 Gap junction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
50 Gastric cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
51 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
52 Glioma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
53 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
54 GnRH secretion 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
55 GnRH signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
56 Growth hormone synthesis, secretion and action 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
57 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
58 Hepatitis B 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
59 Hepatitis C 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
60 Hepatocellular carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
61 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
62 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
63 HIF-1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
64 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
65 Human cytomegalovirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
66 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
67 Human immunodeficiency virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
68 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
69 Human papillomavirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
70 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
71 Human T-cell leukemia virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
72 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
73 Influenza A 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
74 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
75 Insulin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
76 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
77 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
78 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
79 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
80 Long-term depression 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
81 Long-term potentiation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
82 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
83 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
84 MAPK signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
85 Melanogenesis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
86 Melanoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
87 MicroRNAs in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
88 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
89 mTOR signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
90 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
91 Natural killer cell mediated cytotoxicity 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
92 Neurotrophin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
93 Neutrophil extracellular trap formation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
94 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
95 Non-small cell lung cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
96 Oocyte meiosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
97 Osteoclast differentiation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
98 Oxytocin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
99 Pancreatic cancer 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
100 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
101 Parathyroid hormone synthesis, secretion and action 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
102 Pathways in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
103 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
104 Pathways of neurodegeneration - multiple diseases 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
105 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
106 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
107 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
108 Phospholipase D signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
109 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
110 PI3K-Akt signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
111 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
112 Progesterone-mediated oocyte maturation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
113 Prolactin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
114 Prostate cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
115 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
116 Proteoglycans in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
117 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
118 Rap1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
119 Ras signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
120 Regulation of actin cytoskeleton 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
121 Relaxin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
122 Renal cell carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
123 Salmonella infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
124 Serotonergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
125 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
126 Signaling pathways regulating pluripotency of stem cells 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
127 Sphingolipid signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
128 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
129 T cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
130 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
131 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
132 Thyroid cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
133 Thyroid hormone signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
134 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
135 TNF signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
136 Toll-like receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
137 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
138 Vascular smooth muscle contraction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
139 VEGF signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
140 Yersinia infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬

先頭へ